After reading these articles, you should be able to… 

Nonadherence affects roughly one-third of youth with severe mental illness—and those who need medication most are often least likely to take it. This update reviews the most common drivers of nonadherence, from forgetfulness and family dynamics to stigma and motivation, with practical strategies clinicians can apply at every visit.

The placebo effect is real, measurable, and often stronger in children than adults, yet it’s routinely underused. This update explains the neurobiology behind placebo response, how "placebo by proxy" shapes outcomes through caregiver expectations, and how to use open-label placebo approaches ethically and effectively in everyday clinical practice.

Sleep problems are nearly universal in children with ADHD, autism, and chronic illness—but how much can behavioral interventions actually move the needle? A meta-analysis of 15 RCTs examines what changes, what doesn't, and whether the gains last.

Treatment access for adolescent mental health and substance use isn't keeping pace with rising rates. A national survey of over 32,000 youth reveals just how wide the gaps are and why turning 18 may make things measurably worse.

NMS is feared but poorly characterized in pediatric populations. A Medicaid cohort of 1.66 million young antipsychotic users now offers the clearest picture yet of when risk is highest and which combinations clinicians should watch most closely.

Irritability in pediatric ADHD often persists despite stimulant treatment, yet targeted options are limited. Could an NMDA antagonist already sitting on pharmacy shelves offer a safer adjunct? A small pilot trial reports a striking early signal.